For the relief of the symptoms of dyspepsia.

The route of administration is oral.

Recommended Dosage

Adults: 1-2 tablets chewed 4 times daily, taken 20 minutes to 1 hour after meals and at bedtime, or as directed by the physician. A maximum of 8 tablets in a 24 hour period should not be exceeded, nor should the maximum dose continue for more than 2 weeks except under the direction of the physician.

Aluminium hydroxide may cause constipation due to its astringent action, this effect may be balanced by the cathartic effect of the magnesium salts.
Aluminium hydroxide may lead to a phosphate depletion syndrome, particularly in patients on a low phosphate diet e.g. malnutrition.
Magnesium salts may cause central nervous depression in the presence of renal insufficiency and should be used with caution in patients with advance renal disease.
In patients with renal impairment, plasma levels of both aluminium and magnesium increase. In
these patients, a long term exposure to high doses of aluminium and magnesium salts may lead to encephalopathy, dementia, microcytic anemia or worsen dialysis-induced osteomalacia.
The prolonged use of antacid in patients with renal failure should be avoided.
Care should be observed if used by diabetics because of the sugar content of the tablet.
Aluminium hydroxide may be unsafe in patients with porphyria undergoing hemodialysis because it has been shown that aluminium may be involved in porphyrin metabolism abnormalities.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine

This product may form complexes with certain drugs, e.g. tetracyclines, digoxin and vitamins, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.
Concomitant use with quindines may increase the serum levels of quinidine and lead to quinidine overdosage.
Aluminium-containing antacids may prevent the proper adsorption of H2 antagonists, atenolol, chloroquine, cyclines, difunisal, digoxin, diphosphonates, ethambutol, fluroquinolones, sodium fluorure, glucocorticoids, indometacine, isoniazide, kayexalate, ketoconazole, lincosamides, metoprolol, neuroleptics phenothiazines, penicillamine, propranolol, iron salts.
Staggering the administration times of the interacting drug and the antacid by at least 2 hours (4 hours for the fluoroquinolones) will often help avoid undesirable drug interactions.
Aluminium hydroxide and citrates may result in increased aluminium levels, especially in patients with renal impairment.

The product should not be used during pregnancy unless considered essential by the physician

None reported

Gastrointestinal side-effects are uncommon.

Occasionally high doses of antacids may cause diarrhoea or constipation.

Serious symptoms are unlikely following overdosage.

Omacid is a balanced mixture of two antacids: aluminium hydroxide is a slow-acting antacid and magnesium hydroxide is a fast-acting one. The two are frequently combined in antacid mixtures.
Aluminium hydroxide on its own is astringent and may cause constipation. This effect is balanced by the effect of magnesium hydroxide, which, in common with other magnesium salts may cause diarrhoea

The absorption of aluminium and magnesium from antacids is small. Aluminium hydroxide is slowly converted to aluminium chloride in the stomach. Some absorption of soluble aluminium salts occurs in the gastro-intestinal tract with urinary excretion. Any absorbed magnesium is likewise excreted in the urine.

Not relevant

Lactose monohydrate

Methyl Paraben sodium

Propyl Paraben sodium
Sodium Benzoate

Colloidal anhydrous silica
Sodium Saccharin

Sugar

Purified talc

Flavor Peppermint dry

Magnesium stearate

Not applicable

Store below 30C. Protect from light and moisture.

PVDC Coated PVC Blister backed with printed aluminum foil

No special requirements for storage.